Camidge DR, Kim HR, Ahn MJ, Yang JC, et al. Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor-Naive Advanced ALK-Positive Non-Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial. J Thorac Oncol 2021 Aug 30. pii: S1556-0864(21)02398.
PMID: 34537440